Search Results
Your search for ,aLl matches 18306 pages
Showing 17501 - 17550FDA Approves Bevacizumab for Aggressive and Late-Stage Cervical Cancer
The U.S. Food and Drug Administration (FDA) has approved the antiangiogenic agent bevacizumab (Avastin) for the treatment of persistent, recurrent, or metastatic cervical cancer. The new indication is approved for use in combination with paclitaxel and cisplatin or paclitaxel and topotecan. The FDA ...
Researchers Identify Priority Targets for Immunotherapy in Epithelial Ovarian Cancer
Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with clinical outcome in epithelial ovarian cancer. Based on their findings, the researchers have...
ERSPC 13-Year Follow-up: Reduction in Prostate Cancer Mortality With PSA Screening, but High Overdiagnosis Rates Remain a Concern, Say Authors
The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), reported by Schröder et al in The Lancet, showed that prostate-specific antigen (PSA) screening in men aged 55 to 69 years is associated with a 21% reduction in risk of prostate cancer mortality...
Scientists Pinpoint Gene Likely to Promote Childhood Cancers
Researchers at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have identified a gene that contributes to the development of several childhood cancers, in a study conducted in mouse models. If the findings prove to be applicable to humans, the research could...
Prostate Cancer Prevention Trial Identifies Men Most Likely to Undergo Challenging Study Procedures
Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study by Gritz et al published in Cancer Epidemiology, Biomarkers & Prevention. The Prostate Cancer Prevention Trial, ...
Comprehensive Molecular Profiling of Lung Adenocarcinoma
The Cancer Genome Atlas Research Network has recently reported its comprehensive molecular profiling of lung adenocarcinoma in Nature. Findings included a high rate of somatic mutations including alterations in tumor-suppressor genes, chromatin-modifying genes, and RNA-splicing genes and suggested...
U.S. Lung Cancer Rates Vary by Subtype, Sex, Race/Ethnicity, and Age
A new analysis confirms that U.S. lung cancer rates are declining overall, but it also uncovers previously unrecognized trends related to cancer subtype, sex, race/ethnicity, and age. Published early online in Cancer, the findings provide a more accurate picture of the state of lung cancer in the...
Improvements in Overall Survival in Trilateral Retinoblastoma Due to Improved Chemotherapy and Earlier Detection
In a systematic review and meta-analysis reported in The Lancet Oncology, de Jong et al found a dramatic improvement in overall survival among children with trilateral retinoblastoma since 1995, reflecting increased use of conventional and high-dose chemotherapy with stem cell rescue in pineal and...
Negative PET/CT After One Cycle of Chemotherapy Strongly Predicts Favorable Outcome in Hodgkin Lymphoma
Negative 18F–fluorodeoxyglucose positron-emission tomography (PET)/computed tomography (CT) after two cycles of chemotherapy (PET2) has been shown to be associated with favorable prognosis in Hodgkin lymphoma. In a prospective study reported in the Journal of Clinical Oncology, Hutchings et...
Adding Gemtuzumab Ozogamicin to Chemotherapy Improves Event-Free Survival but Not Overall Survival in Children and Adolescents With De Novo AML
In a Children’s Oncology Group phase III trial reported in the Journal of Clinical Oncology, Gamis et al found that the addition of gemtuzumab ozogamicin (Mylotarg), an immunoconjugate targeting CD33, resulted in significantly prolonged event-free survival but not overall survival when added...
Genome-Wide Association Study Finds New Genetic Risk Markers in Pancreatic Cancer
A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, reported scientists from Dana-Farber Cancer Institute. The study by Wolpin et al was published in Nature Genetics. The...
Medicaid or No Insurance Associated With Worse Cancer-Specific Survival in Nonelderly Patients
In a study reported in the Journal of Clinical Oncology, Walker et al found that among nonelderly patients with the top 10 most lethal cancers, those with Medicaid or no insurance were more likely to present with advanced disease and less likely to receive cancer-directed surgery or radiation...
Large Differences in Survival According to Hospital Risk-Adjusted Margin Positivity Rate Status in Rectal Cancer Surgery
Risk-adjusted margin positivity rate has been suggested for use as a rectal cancer surgery quality metric. In an observational cohort study reported in the Journal of Clinical Oncology, Massarweh et al from The University of Texas MD Anderson Cancer Center identified risk-adjusted margin positivity ...
Statin Use After Colorectal Cancer Diagnosis Reduces Colorectal Cancer–Specific and All-Cause Mortality
In a UK population-based cohort study reported in the Journal of Clinical Oncology, Cardwell et al found that statin use after diagnosis of colorectal cancer was associated with a 29% reduction in colorectal cancer–specific mortality and a 25% reduction in all-cause mortality. Improvements...
College of American Pathologists Publishes Recommendations for Prostate Cancer Active Surveillance
Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. In a recent article in the Archives of Pathology & Laboratory Medicine, a...
No Difference in Complication Rates or Hospital Stay With Robot-Assisted vs Open-Surgery Cystectomy in Bladder Cancer
In a trial reported in The New England Journal of Medicine, Bochner et al found no difference in complication rates or length of hospital stay with robot-assisted laparoscopic radical cystectomy vs open surgery in patients with bladder cancer. Blood loss was greater and procedure time shorter with...
Significant Variation in Use of Single-Fraction Radiation Therapy for Palliation of Bone Metastases
Standardizing prescribing practices for single-fraction radiation therapy for palliation of bone metastases could lead to cost savings and improvement in patients’ quality of life, according to a study published in the August issue of the International Journal of Radiation Oncology •...
Tumor Downstaging After Neoadjuvant Chemotherapy Strongly Predicts Improved Outcome After Surgery in Esophageal and Esophagogastric Junction Cancer
In a European analysis reported in the Journal of Clinical Oncology, Davies et al found that pathologic tumor downstaging after neoadjuvant chemotherapy was the strongest independent predictor of overall survival in patients undergoing surgery for esophageal and esophagogastric junction...
Study Suggests Recent Use of Some Birth Control Pills May Be Associated With Increased Breast Cancer Risk
Women who recently used birth control pills containing high-dose estrogen and a few other formulations had an increased risk for breast cancer, whereas women using some other formulations did not, according to data published in Cancer Research. “Our results suggest that use of contemporary...
HLA Matching Finds Suitable Donors for Majority of Hematopoietic Stem Cell Transplant Candidates
A study reported by Gragert et al in The New England Journal of Medicine indicates that most candidates for hematopoietic stem cell transplantation in the United States will have a suitable adult donor on the basis of HLA matching, although many will not have optimal donors. Few will have optimal...
Phase II Trial Shows Activity of Pemetrexed Plus Cisplatin in Treatment of Advanced, Persistent, or Recurrent Cervical Carcinoma
In a phase II Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Miller et al found that the combination of pemetrexed (Alimta) and cisplatin produced responses in the treatment of advanced, persistent, or recurrent cervical cancer. In the study, 54 patients from...
Minimal Residual Disease–Based Risk-Directed Therapy Is Effective in Children With BCR-ABL1–Like B-Cell ALL
BCR-ABL1–like acute lymphoblastic leukemia (ALL), a recently identified B-cell ALL subtype associated with poor outcome, has a gene-expression profile similar to BCR-ABL1–positive disease without the presence of the BCR-ABL1 fusion protein. In a retrospective analysis reported in the...
Adults With Exclusively Pulmonary Metastases From Ewing Sarcoma May Benefit From Whole-Lung Irradiation
Nearly half of adult patients with lung-only metastases from Ewing sarcoma who received whole-lung irradiation were free of pulmonary relapse at 3 years, according to the results of a retrospective study in the International Journal of Radiation Oncology • Biology • Physics. With few...
Acupuncture Provides Significant Quality-of-Life Improvements Among Breast Cancer Patients With Aromatase Inhibitor–Related Joint Pain
Use of electroacupuncture—a form of acupuncture where a small electric current is passed between pairs of acupuncture needles—produces significant improvements in fatigue, anxiety, and depression in as little as 8 weeks for early-stage breast cancer patients experiencing joint pain...
Phase Ib Study Shows Activity of Ibrutinib Plus R-CHOP in First-Line Treatment of CD20-Positive B-Cell Non-Hodgkin Lymphoma
The oral Bruton's tyrosine kinase inhibitor ibrutinib (Imbruvica) has shown activity in relapsed and refractory B-cell malignancies. In a phase Ib trial reported in The Lancet Oncology, Younes et al identified no maximum tolerated dose of ibrutinib when combined with R-CHOP (rituximab [Rituxan],...
Study Helps Compare Risks of Endoscopic vs Surgical Resection for Early Esophageal Cancer
A new study published in the Journal of the National Cancer Institute by researchers at Northwestern Medicine shed new light on the risks associated with the growing popularity of endoscopic resection in the treatment of localized, early-stage esophageal cancer. Merkow et al found that the...
Promising Phase Ib Findings With Combined BRAF and MEK Inhibition With Vemurafenib and Cobimetinib in Advanced BRAF V600–Mutant Melanoma
In a phase Ib study reported in The Lancet Oncology, Ribas et al found that the combination of the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib was safe and active in the treatment of advanced BRAF V600–mutant melanoma. Preclinical studies have shown that the...
Failure to Adopt a Healthy Lifestyle More Than Doubles Risk of Metabolic Syndrome in Childhood Cancer Survivors
A St. Jude Children’s Research Hospital study found that 73% of adult survivors of childhood cancer more than doubled their risk of developing metabolic syndrome and related health problems by failing to follow a heart-healthy lifestyle. The results were published online in the journal...
First Surveillance Imaging at 6 Months May Be Adequate for Most Patients After Treatment for Early-Stage Non‒Small Cell Lung Cancer
Early surveillance imaging (< 6 months) after stereotactic body radiation therapy for early-stage non–small cell lung cancer (NSCLC) seems to be of limited benefit, resulting in definitive intervention in only 3% of patients, according to the findings of a study in Practical Radiation...
New Molecular Test Increases Odds of Correct Surgery for Thyroid Cancer Patients
The routine use of a molecular testing panel developed at the University of Pittsburgh Medical Center greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer, reported researchers from the University of Pittsburgh Cancer Institute. The ...
Adaptive Intensity-Modulated Radiation Therapy Strategy May Ensure Adequate Target Coverage in Patients With Cervical Cancer
A novel, dosimetry-triggered, adaptive intensity-modulated radiation therapy strategy for patients with cervical cancer may minimize the risk of target underdosing in the setting of very small margins and substantial interfractional motion, according to a study by Lim et al in the International...
Higher Plasma Vitamin D Concentration Associated With Reduced Cancer-Specific and All-Cause Mortality After Diagnosis of Colorectal Cancer
In a Scottish study reported in Journal of Clinical Oncology, Zgaga et al found strong associations between plasma levels of 25-hydroxyvitamin D (25-OHD) after a diagnosis of colorectal cancer and colorectal cancer–specific and all-cause mortality. Significant interactions of vitamin D...
Combined BRAF V600E and TERT Promoter Mutations Identify Aggressive and Recurrent Papillary Thyroid Cancer
In a study reported in Journal of Clinical Oncology, Xing et al found that the combined presence of BRAF V600E and TERT C228T mutations was associated with increased risk of recurrence and poor disease-free survival in patients with papillary thyroid cancer. The retrospective study included 365...
FDA Approves Idelalisib for Three Types of Blood Cancers
The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig) for the treatment of patients with three types of blood cancers. Idelalisib is being granted traditional approval to treat patients with relapsed chronic lymphocytic leukemia (CLL). Used in combination with rituximab...
Study Defines Four Molecular Subtypes of Gastric Cancer
Investigators of The Cancer Genome Atlas project have developed a molecular classification that divides gastric cancer into four major genomic subtypes, according to a study published in Nature. They include (1) tumors positive for the Epstein-Barr virus (EBV) that display recurrent PIK3CA...
Metabolic Enzyme Stops Growth of Most Common Type of Kidney Cancer
In an analysis of metabolites in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth. The new study, published in Nature by Simon et al, demonstrated that an enzyme called FBP1,...
Depression Associated With Less Definitive Therapy and Poorer Survival in Men With Clinically Localized Prostate Cancer
In a population-based cohort study reported in the Journal of Clinical Oncology, Prasad et al found that men with depressive disorder prior to prostate cancer diagnosis were significantly less likely to undergo definitive therapy and had worse overall survival across all risk strata compared with...
No Disease-Free Survival Benefit of Adjuvant Zoledronic Acid in High-Risk Patients With Early Breast Cancer
In the open-label phase III AZURE trial reported in The Lancet Oncology, Coleman et al found that adjuvant zoledronic acid treatment in patients with high-risk early-stage breast cancer provided no overall disease-free survival benefit. A reduction in bone metastases was observed, and women who...
Noninvasive Image Texture Analysis May Provide Tumor Heterogeneity Information With Prognostic Potential in NSCLC
Noninvasive quantitative computed tomography–based texture analysis can accurately differentiate the presence of a KRAS mutation from pan–wild-type non–small cell lung cancer (NSCLC), based on the results of a study in PLOS ONE. Weiss et al reported that this tumor heterogeneity...
Integrated Safety Analysis Shows Favorable Safety Profile of Single-Agent Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
The antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) is currently indicated in the United States for treatment of patients with HER2-positive metastatic breast cancer who previously received trastuzumab (Herceptin) and a taxane and who have either received prior therapy for metastatic...
Improved Survival in Hematologic Malignancies in Europe Between 1997 and 2008
As reported by Sant et al in The Lancet Oncology, the population based EUROCARE-5 study has shown significantly improved survival in hematologic malignancies in Europe between 1997 and 2008. Although improved, survival was poorer in Eastern Europe compared with other regions. Study Details This...
Two Common Gene Variants Associated With Longer Telomere Length May Increase the Risk of Glioma
Two common gene variants that lead to longer telomere length may increase the risk of glioma, according to the results of a study presented by Walsh et al in Nature Genetics. This finding suggests that telomere length may prove to be a promising epidemiologic risk factor for cancer. It is well...
Minority of Older Patients With Low-Risk Prostate Cancer Managed by Observation
Most older men with low-risk prostate cancer receive upfront treatment, despite absence of clear survival benefit and potential for morbidity. In a retrospective cohort study reported in JAMA Internal Medicine, Hoffman et al found that use of observation as management in this setting varied widely...
No Clinical Outcome Benefit With Aerobic Training Program in Cancer Patients With Heart Failure
In a retrospective analysis in the HF-ACTION trial reported in the Journal of Clinical Oncology, Jones et al found that a program of aerobic training did not reduce the rate of all-cause mortality or hospitalization in cancer patients with heart failure. Some evidence suggested that patients who...
Lymphovascular Invasion and Regression Identified as Independent Prognostic Factors in Thin Melanoma
In a European study reported in the Journal of Clinical Oncology, Maurichi et al identified lymphovascular invasion and regression as important prognostic factors in thin melanoma. They developed a nomogram including age, mitotic rate, ulceration, lymphovascular invasion, regression, and sentinel...
New Androgen Receptor Inhibitor Shows Activity in Metastatic Castration-Resistant Prostate Cancer
ODM-201 is a novel androgen receptor inhibitor—structurally distinct from enzalutamide (Xtandi)—that acts via high-affinity binding to the androgen receptor and inhibition of receptor nuclear translocation. In the phase I/II ARADES trial reported in The Lancet Oncology, Fizazi et al...
Gene Signature May Predict Which Breast Cancer Patients Will Benefit From Tamoxifen
A novel approach using ChIP-seq and RNA-seq analysis in combination with RNA expression data has identified a gene called USP9X that may predict which patients with estrogen receptor–positive breast cancer will benefit from tamoxifen therapy after surgery. The gene signature the researchers...
Blocking Tumor-Derived Protein Halts Cachexia in Preclinical Study
New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle occurring in about half of all cancer patients, raising their risk of death, according to scientists from Dana-Farber Cancer Institute. In a study reported in Nature, Spiegelman et al...
Study Compares Tamoxifen Gel Applied to the Breast With Oral Tamoxifen in Women With DCIS
A randomized, double-blind, placebo-controlled phase II trial comparing the antiproliferative effect of transdermal 4-hydroxytamoxifen gel (4-OHT), a potent antiestrogenic metabolite of tamoxifen, applied to the breast and oral tamoxifen in women with ductal carcinoma in situ (DCIS), has found the...
Testicular Cancer Rates Are on the Rise in Young Hispanic Americans
A new analysis has found that rates of testicular cancer have been rising dramatically in recent years among young Hispanic American men, but not among their non-Hispanic counterparts. Published early online in Cancer, the findings indicate that greater awareness is needed concerning the increasing ...
